Grant Skrepnek to Anti-Bacterial Agents
This is a "connection" page, showing publications Grant Skrepnek has written about Anti-Bacterial Agents.
Connection Strength
0.700
-
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. Curr Med Res Opin. 2005 Feb; 21(2):261-70.
Score: 0.174
-
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect. 2019 Aug; 25(8):987-993.
Score: 0.114
-
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther. 2019 Apr; 44(2):220-228.
Score: 0.112
-
Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017 Dec; 18(12):e615-e620.
Score: 0.106
-
Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. J Oncol Pharm Pract. 2019 Apr; 25(3):520-528.
Score: 0.105
-
Administration of first dose antibiotic in the ED in patients with minor skin and soft tissue infections. Am J Emerg Med. 2015 Sep; 33(9):1225-8.
Score: 0.089